# A Phase 2b Diabetic Kidney Disease Study

Study · id `cardio:ct-nct04170543` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04170543](<https://clinicaltrials.gov/study/NCT04170543>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04170543

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 609 participants.

## Technical summary

Registry record NCT04170543. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-18 (actual); primary completion 2023-05-16 (actual). Results posted on 2024-07-10.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 609 participants (enrolled count; ClinicalTrials.gov record NCT04170543, source copy `cardio:ctgov-nct04170543-2024-07-10`, retrieved 2026-10-26)
- Started: 2019-11-18 (actual) (ClinicalTrials.gov record NCT04170543, source copy `cardio:ctgov-nct04170543-2024-07-10`, retrieved 2026-10-26)
- Primary completion: 2023-05-16 (actual) (ClinicalTrials.gov record NCT04170543, source copy `cardio:ctgov-nct04170543-2024-07-10`, retrieved 2026-10-26)
- Completion: 2023-05-16 (actual) (ClinicalTrials.gov record NCT04170543, source copy `cardio:ctgov-nct04170543-2024-07-10`, retrieved 2026-10-26)
- Results first posted: 2024-07-10 (ClinicalTrials.gov record NCT04170543, source copy `cardio:ctgov-nct04170543-2024-07-10`, retrieved 2026-10-26)
- Countries: United States; Argentina; Canada; Chile; Japan; Peru; South Korea (ClinicalTrials.gov record NCT04170543, source copy `cardio:ctgov-nct04170543-2024-07-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04170543-2024-07-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2b Diabetic Kidney Disease Study
- Condition: Diabetic Kidney Disease
- Intervention (Drug): MEDI3506
- Intervention (Drug): Placebo
- Intervention (Drug): Dapagliflozin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial (`cardio:pubmed-41563367`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f2361da776f9c97060ff37f131eec66ca978eee47f7383fe44f6e35676b8c8ec
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
